Dr. Erick Mora Ramírez

Puesto: Profesor

Oficina: Laboratorio Ciclotrón - PET/CT

Teléfono: 2511-4935

Especialización/Intereses de investigación: Física Médica, Protección Radiológica/Dosimetría/Cuantificación (2D - 3D)/Control de Calidad en Medicina Nuclear, Monte Carlo, Educación

Estudios Universitarios:

Doctorado en Ciencias para la Ingeniería Especialidad Radiofísica e Imágenes Médicas, Université Paul Sabatier, Toulouse, Francia (2019)
Maestría en Ciencias de la Educación con Énfasis en Docencia, UAM, San José, Costa Rica, (2021)
Maestría en Física de Radiaciones, University College London, Londres, Inglaterra (2005)
Bachillerato Universitario en Física, Universidad de Costa Rica, San José, Costa Rica, (2003)

Publicaciones:

Kayal G., Chauvin M., Mora-Ramirez E., Clayton N., Vergara-Gil A., Tran-Gia J., Lassmann M., Calvert N., Tipping J., Struelens L., Bardiès M., MRTDosimetry Collaboration, “Modelling SPECT auto-contouring acquisitions for 177Lu & 131I molecular radiotherapy using new developments in Geant4/GATE”, Physica Medica, 2022; 96, 101 – 113 (DOI: 10.1016/j.ejmp.2022.03.003)
Herrera-Sanchez S., Corrales-Corrales E., Noguera-Vega G., Mora-Ramirez E., “Characterization of Geiger-Müller radiation detectors response at the University of Costa Rica’s Cyclotron Facilities”, J. Health. Med. Sci. 2021, 7 (4), 231 – 238.
Santoro L, Pitalot L., Trauchessec D, Mora-Ramirez E, Kotzki P O, Bardiès M, Deshayes E. “Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0”. EJNMMI Research. 2021 11, 1. (DOI: 10.1186/s13550-020-00737-8)
Erick Mora-Ramirez, Lore Santoro, Emmanuelle Cassol, Juan c. Ocampo-Ramos, Naomi Clayton, Gunjan Kayal, Soufiane Chouaf, Dorian Trauchessec, Jean-Pierre Pouget, Pierre-Oliver Kotzki, Emmanel Deshayes, Manuel Bardiès, “Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy”. Medical Physics, 2020; 47(9): 4602 - 4615 (DOI:10.1002/mp.14375)
Chauvin M., Borys D., Botta F., Bzowski P., Dabin J., Denis-Bacelar A., Desbrée A., Falzone N., Lee B. Q., Mariani A., Malaroda A., Mathieu G., McKay E., Mora-Ramirez E., Robison A. P., Sarrut D., Struelens L., Vergara-Gil A., Manuel Bardiès, “OpenDose: Open access resources for nuclear medicine dosimetry”. J Nucl Med, 2020, 61: 1514 - 1519 (DOI:10.2967/jnumed.119.240366)
Julien Bordes, Sebatien Incerti, Erick Mora-Ramirez, Jonathan Tranel, Cédirc Rossi, Christine Bezombes, Julie Bordenave, Manuel Bardiès, Richard Brown, Marie-Claude Bordage, “Monte Carlo dosimetry of a realistic multicellular of follicular lymphoma in a context of radioimmunotherapy”. Medical Physics, 2020; 47(10): 5222 - 5234 (DOI: 10.1002/mp.14370)
Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget J P, Kotzki P O, Bardiès M, Deshayes E. “Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTATO,Tyr3]-octreotate]”. EJNMMI Research. 2018; 8: 103.
Zoppolo F, Mora-Ramirez E, Reyes A L, Vasilskis E, Paolino A, Porcal W, Oliver P, Savio E, Bardies M, Engler H. “Biological and dosimetric evaluation of [11C]S-adenosyl methionine as a potential agent for prostate cancer diagnosis”. Cancer Research Frontiers. 2018;4(1): 27-44. DOI:10.17980/2018.27.
Kreimerman I, Mora-Ramirez E, Reyes AL, Bardies M, Savio E, Engler H. “Dosimetry and toxicity studies of the novel sulfonamide derivative of Sulforhodamine 101([18F]SRF101) at a preclinical level”. Curr. Radiopharm. 2019;12(1): 40-48. DOI: 10.2174/1874471011666180830145304.
Salabert A-S, Mora-Ramirez E, Beaurain M, Alonso M, Fontan C, Tahar HB, Boizeau ML, Tafani M, Bardiés M, Payoux P. “Evaluation of [18F] FNM biodistribution and dosimetry based on whole-body PET imaging of rats”. Nucl. Med. Biol. 2018;59:1–8.
Estrada-Lobato E, Alonso-Farto J C, De Haro-Del Moral F J, Cerci J J, Rodriguez-Perez J L, Vazquez-Peña E, Godinho F, Mora-Ramirez E, Tinoco-Mezquita F, Mut-Bastos F, Savio-Quevedo E O, Penedo-Ojea M, Ramirez-Quijada R. “Sesion Medicina Nuclear”, Radioproteccion, 87: 34-39, 2017.
Mora Araya L D, Mora Ramirez E, Salas Ramirez M, Mora Zeledon I. “Estimacion del factor de calibracion de una gamma camara en un medio de atenuacion”, Rev. Latinoame. Fis. Méd, 1(2): 108-111, 2015
Mora Araya L D, Mora Ramirez E, Salas Ramirez M, Mora Zeledon I. “Analisis del impacto de la limitada resolucion espacial y del factor de calibracion utilizado en la cuantificacion de imágenes palanares de medicina nuclear”, Rev. Latinoame. Fis. Méd, 1(2): 112-116, 2015
Mora-Ramírez E, Salas-Ramírez M. (28/07/2015). “Calibración de una sonda de captación para la monitorización del Personal Ocupacionalmente Expuesto”. Alasbimn Journal, ISSN: 0717 - 4055. URL: http://www.alasbimnjournal.net/a/153
Mora-Ramírez E, Mora Zeledón I, Salas Ramírez M. (19/02/2014). “Evaluación de la uniformidad intrínseca de gamma cámaras en dos hospitales de la Caja Costarricense del Seguro Social”. Alasbimn Journal, ISSN: 0717 - 4055. URL: http://www.alasbimnjournal.net/a/54
Mora-Ramírez E, Mora-Zeledon I. (10/02/2012). “Curva de calibración para estándares utilizados en tratamientos de cáncer de tiroides”. Alasbimn Journal, ISSN: 0717 - 4055. URL: http://www.alasbimnjournal.net/a/51
E Mora-Ramírez, P Mora-Rodríguez, M Salas-Ramírez. “Estimación de la dosis absorbida en pacientes que reciben tratamiento terapéutico con 131I por cáncer de tiroides”, PROCEEDINGS V ALFIM 2010, http://www.spfmperu.org/cusco2010/index.html (also available in RESEARCHGATE).
E Mora-Ramírez, C Fonseca-Zamora, U González-Solano, M Salas-Ramírez. “Implementación de guías con recomendaciones de protección radiológica para pacientes que reciben tratamiento terapéutico con 131I por hipertiroidismo”, PROCEEDINGS V ALFIM 2010, http://www.spfmperu.org/cusco2010/index.html (also available in RESEARCHGATE).
E Mora-Ramírez, C Fonseca-Zamora, U González-Solano, M Salas-Ramírez. “Implementación de guías con recomendaciones de protección radiológica para pacientes con cáncer de tiroides que reciben tratamiento terapéutico con 131I”, PROCEEDINGS V ALFIM 2010, http://www.spfmperu.org/cusco2010/index.html (also available in RESEARCHGATE).
Mora-Ramírez E, Zeledón-Fonseca P, Jiménez-Cordero M. “Radionuclide Calibrator Performance Evaluation”, PROCEEDINGS 12th IRPA 2008, http://www.irpa12.org.ar/index.php.
Mora-Ramírez E. “Intrinsic Flood-Field Uniformity Evaluation”, PROCEEDINGS 12th IRPA 2008, http://www.irpa12.org.ar/index.php.
P Mora, E Mora. Monitoreo Ambiental con Detectores Termoluminiscentes en Costa Rica, Revista Ciencia y Tecnología, Vol. 24: 21-30, 2006.

Publicaciones: Resúmenes (Abstracts) Publicados:

Vergara-Gil A., Amato E., Auditore L., Brenet M., Chauvin M., Clayton N., Ferrer L., Gibaud B., Gnesin S., Italiano A., Kayal G., Lima T., J. Ocampo, Pistone D., Quan G., Mora-Ramirez E., Ruegger J., Bardiès M., (Abstract OP-622). “OpenDose3D: A fre, collaborative 3D Slicer module for patient-specifi dosimetry”. Eur J Nucl Med Mol Imaging, 2020; 47 (Suppl 1): S314.
Taprogge J., Leek F., Bardiès M., Buck A., Clayton N., Courbon F., Eberlein U., Lapa C., Lassman M., Luster M., Mora-Ramirez E., Newbold K., Schlöng S., Schumann S., Schurrat T., Trans-Gia J., Vallot D., Verburg F., Vija L., Vergara-Gil A., Zerdoud S., Flux D.G. (Abstract OP-625). “The MEDIRAD Imaging network – Standarization of quantitative radioiodine imaging”. Eur J Nucl Med Mol Imaging, 2020; 47 (Suppl 1): S316.
Kayal G., Chauvin M., Mora-Ramirez E., Struelens L., Bardiès M., (Abstract OP-629). “Implementation of SPECT auto-contoring detector motion in GATE Monte Carlo simulation for 177Lu and 131I Molecular Radiotherapy (MRT) dosimetry”. Eur J Nucl Med Mol Imaging, 2020; 47 (Suppl 1): S318.
Mora-Ramirez E., Vergara-Gil A., Ocampo-Ramos J., Pouget J., Kotzki P., Santoro L., Deshayes E., Bardiès M., (Abstract – OP-206). “Absorbed dose calculation considering organ mass variation for patients treated with Lutathera”. Eur J Nucl Med Mol Imaging. 2019, 46 (Suppl 1): S86.
Leek F., Taprogge J., Gregory R., Newbold K., Verburg F., Luster M., Schurrat T., Trans-Gia J., Eberlein U., Lapa C., Buck A. K., Lassman M., Mora-Ramirez E., Vergara-Gil A., Bardiès M., Vallot D., Courbon F., Vija L., , Flux G. (Abstract OP-502). “The MEDIRAD multi-national I-131 dosimetry study for thyroid ablation and adjuvant therapy: current status”. Eur J Nucl Med Mol Imaging, 2019; 46 (Suppl 1): S194.
Vergara-Gil A., Mora-Ramirez E., Pouget J., Kotzki P., Santoro L., Deshayes E., Bardiès M., (Abstract – EP-0198). “Fast heterogeneous convolution algorithm used in absorbed dose calculation for beta emitters”. Eur J Nucl Med Mol Imaging. 2019, 46 (Suppl 1): S473.
Ocampo-Ramos J., Mora-Ramirez E., Bardiès M., (Abstract – EP-0972). “Evolution and evaluation of effective dose in the context of diagnotics nuclear medicine”. Eur J Nucl Med Mol Imaging. 2019, 46 (Suppl 1): S837.
Mora-Ramirez E, Cassol E, Santoro L, Chouaf S, Trauchessec D, Pouget P, Kotzki P, Deshayes E, Bardiès M., “Comparison of organ-based absorbed doses estimations by using PLANET®Dose and OLINDA/EXM V2.0 in patients with peptide receptor radionuclide therapy (PRRT) treated with Lutathera®” (Abstract-60). Physica Medica, 2018, 56 (Suppl 1): 34.
Mora-Ramirez E, Cassol E, Ocampo-Ramos J C, Chouaf S, Trauchessec D, Pouget P, Kotzki P, Santoro L, Deshayes E, Bardiès M. (Abstract – OP-557). “Comparsion between PLANET®Dose and OLINDA/EXM V2.0 in organ-based absorbed doses estimations for patients treated with Lutathera®”. Eur J Nucl Med Mol Imaging. 2018, 45 (Suppl 1): S180.
Leek F, Gregory R, Newbold K, Verburg FA, Luster M, Schurrat T, Lassmann M, Eberlein U, Buck AK, Lapa C, Bardiès M, Mora-Ramirez E, Vallot D, Courbon F, Vija L, Flux G. (Abstract – EP-0166). “The MEDIRAD multi-national I-131 Dosimetry study for thyroid ablation and adjuvant therapy”. Eur J Nucl Med Mol Imaging. 2018,45 (Suppl 1): S359.
Mora-Ramirez E, Ocampo-Ramos JC, Cassol E, Stiles B, Chouaf S, Trauchessec D, Pouget P, Kotzki P, Santoro L, Deshayes E, Bardiès M. (Abstract – EP-0170). “Red Marrow dosimetry without whole-body measurements for patients treated with Lutathera®”. Eur J Nucl Med Mol Imaging. 2018,45 (Suppl 1): S361.
Savio E, Kreimerman I, Mora-Ramirez E, Reyes A, Bardiès M, Engler H. (Abstract – EP-0836). “Toxicological and dosimetric assessement of a 18F-Sulforhodamine 101 derivative as a novel radiotracer for PET imaging of astrocytosis”. Eur J Nucl Med Mol Imaging. 2018,45 (Suppl 1): S638.
Mora-Ramirez E, Santoro L, Trauchessec D, Chouaf S, Deshayes E, Pouget P, Kotzki P, Bardiès M. (Abstract – EP-0887). “SPECT/CT calibration using clinical dosimetry workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE”. Eur J Nucl Med Mol Imaging. 2017,44 (Suppl 1): S809.
Mora-Ramirez E, Santoro L, Trauchessec D, Chouaf S, Deshayes E, Pouget P, Kotzki P, Bardiès M. (Abstract – EP-0888). “Dosimetric estimations using commecial workstations for peptide receptor radionuclide therapy (PRRT) in patients treated with 177Lu-DOTATATE”. Eur J Nucl Med Mol Imaging. 2017,44 (Suppl 1): S810.
Salas M, Mora E. (Abstract – P028). “Radiation protection recommendations for releasing patients treated with 131I for thyroid cancer”. Eur J Nucl Med Mol Imaging. 2015, 42 (Suppl 1): S353.
Mora-Ramirez E. (Abstract – PW099). “Theoretical model for release of patients with benign thyroid disease based on parameters obtaied from EANM standard operational procedures for Pre-Therapeutic Dosimetry II”. Eur J Nucl Med Mol Imaging. 2015, 42 (Suppl 1): S328.
Mora-Ramirez E, Mora-Zeledon I, Salas-Ramirez M, Mora-Rodriguez P. (Abstract – P0160). “Absorbed dose estimation for red marrow in patients with thyroid cancer treated with 131I in Costa Rica”. Eur J Nucl Med Mol Imaging. 2012,39 (Suppl 2): S344.
Hutton, B F, Kacperski K, Mora-Ramirez E. (Abstract). “Performance evaluation: the need for relevant methodology for cardiac-specific SPECT”, Journal of Nuclear Medicine, Meeting Abstracts, 48: 428P, 2007.
Mora-Ramirez E, Barden L, Hutton B F. (Abstract). “Improved Triple Energy Window Scatter Correction for 131I”, Nucl. Med. Comm. 27, 2006.